Research ArticleArticle
Demonstration of the Innate Electrophilicity of 4-(3-(Benzyloxy)phenyl)-2-(ethylsulfinyl)-6-(trifluoromethyl)pyrimidine (BETP), a Small-Molecule Positive Allosteric Modulator of the Glucagon-Like Peptide-1 Receptor
Heather Eng, Raman Sharma, Thomas S. McDonald, David J. Edmonds, Jean-Philippe Fortin, Xianping Li, Benjamin D. Stevens, David A. Griffith, Chris Limberakis, Whitney M. Nolte, David A. Price, Margaret Jackson and Amit S. Kalgutkar
Drug Metabolism and Disposition August 2013, 41 (8) 1470-1479; DOI: https://doi.org/10.1124/dmd.113.052183
Heather Eng
Pharmacokinetics, Dynamics and Metabolism–New Chemical Entities, Groton, Connecticut (H.E., R.S., T.S.M.) and Cambridge, Massachusetts (A.S.K.); Cardiovascular, Metabolic and Endocrine Diseases Medicinal Chemistry, Cambridge (D.J.E., B.D.S., D.A.G., W.M.N., D.A.P.) and Groton (C.L.); and Cardiovascular, Metabolic and Endocrine Diseases Research Unit, Cambridge (J.-P.F., X.L., M.J.) Pfizer, Inc.
Raman Sharma
Pharmacokinetics, Dynamics and Metabolism–New Chemical Entities, Groton, Connecticut (H.E., R.S., T.S.M.) and Cambridge, Massachusetts (A.S.K.); Cardiovascular, Metabolic and Endocrine Diseases Medicinal Chemistry, Cambridge (D.J.E., B.D.S., D.A.G., W.M.N., D.A.P.) and Groton (C.L.); and Cardiovascular, Metabolic and Endocrine Diseases Research Unit, Cambridge (J.-P.F., X.L., M.J.) Pfizer, Inc.
Thomas S. McDonald
Pharmacokinetics, Dynamics and Metabolism–New Chemical Entities, Groton, Connecticut (H.E., R.S., T.S.M.) and Cambridge, Massachusetts (A.S.K.); Cardiovascular, Metabolic and Endocrine Diseases Medicinal Chemistry, Cambridge (D.J.E., B.D.S., D.A.G., W.M.N., D.A.P.) and Groton (C.L.); and Cardiovascular, Metabolic and Endocrine Diseases Research Unit, Cambridge (J.-P.F., X.L., M.J.) Pfizer, Inc.
David J. Edmonds
Pharmacokinetics, Dynamics and Metabolism–New Chemical Entities, Groton, Connecticut (H.E., R.S., T.S.M.) and Cambridge, Massachusetts (A.S.K.); Cardiovascular, Metabolic and Endocrine Diseases Medicinal Chemistry, Cambridge (D.J.E., B.D.S., D.A.G., W.M.N., D.A.P.) and Groton (C.L.); and Cardiovascular, Metabolic and Endocrine Diseases Research Unit, Cambridge (J.-P.F., X.L., M.J.) Pfizer, Inc.
Jean-Philippe Fortin
Pharmacokinetics, Dynamics and Metabolism–New Chemical Entities, Groton, Connecticut (H.E., R.S., T.S.M.) and Cambridge, Massachusetts (A.S.K.); Cardiovascular, Metabolic and Endocrine Diseases Medicinal Chemistry, Cambridge (D.J.E., B.D.S., D.A.G., W.M.N., D.A.P.) and Groton (C.L.); and Cardiovascular, Metabolic and Endocrine Diseases Research Unit, Cambridge (J.-P.F., X.L., M.J.) Pfizer, Inc.
Xianping Li
Pharmacokinetics, Dynamics and Metabolism–New Chemical Entities, Groton, Connecticut (H.E., R.S., T.S.M.) and Cambridge, Massachusetts (A.S.K.); Cardiovascular, Metabolic and Endocrine Diseases Medicinal Chemistry, Cambridge (D.J.E., B.D.S., D.A.G., W.M.N., D.A.P.) and Groton (C.L.); and Cardiovascular, Metabolic and Endocrine Diseases Research Unit, Cambridge (J.-P.F., X.L., M.J.) Pfizer, Inc.
Benjamin D. Stevens
Pharmacokinetics, Dynamics and Metabolism–New Chemical Entities, Groton, Connecticut (H.E., R.S., T.S.M.) and Cambridge, Massachusetts (A.S.K.); Cardiovascular, Metabolic and Endocrine Diseases Medicinal Chemistry, Cambridge (D.J.E., B.D.S., D.A.G., W.M.N., D.A.P.) and Groton (C.L.); and Cardiovascular, Metabolic and Endocrine Diseases Research Unit, Cambridge (J.-P.F., X.L., M.J.) Pfizer, Inc.
David A. Griffith
Pharmacokinetics, Dynamics and Metabolism–New Chemical Entities, Groton, Connecticut (H.E., R.S., T.S.M.) and Cambridge, Massachusetts (A.S.K.); Cardiovascular, Metabolic and Endocrine Diseases Medicinal Chemistry, Cambridge (D.J.E., B.D.S., D.A.G., W.M.N., D.A.P.) and Groton (C.L.); and Cardiovascular, Metabolic and Endocrine Diseases Research Unit, Cambridge (J.-P.F., X.L., M.J.) Pfizer, Inc.
Chris Limberakis
Pharmacokinetics, Dynamics and Metabolism–New Chemical Entities, Groton, Connecticut (H.E., R.S., T.S.M.) and Cambridge, Massachusetts (A.S.K.); Cardiovascular, Metabolic and Endocrine Diseases Medicinal Chemistry, Cambridge (D.J.E., B.D.S., D.A.G., W.M.N., D.A.P.) and Groton (C.L.); and Cardiovascular, Metabolic and Endocrine Diseases Research Unit, Cambridge (J.-P.F., X.L., M.J.) Pfizer, Inc.
Whitney M. Nolte
Pharmacokinetics, Dynamics and Metabolism–New Chemical Entities, Groton, Connecticut (H.E., R.S., T.S.M.) and Cambridge, Massachusetts (A.S.K.); Cardiovascular, Metabolic and Endocrine Diseases Medicinal Chemistry, Cambridge (D.J.E., B.D.S., D.A.G., W.M.N., D.A.P.) and Groton (C.L.); and Cardiovascular, Metabolic and Endocrine Diseases Research Unit, Cambridge (J.-P.F., X.L., M.J.) Pfizer, Inc.
David A. Price
Pharmacokinetics, Dynamics and Metabolism–New Chemical Entities, Groton, Connecticut (H.E., R.S., T.S.M.) and Cambridge, Massachusetts (A.S.K.); Cardiovascular, Metabolic and Endocrine Diseases Medicinal Chemistry, Cambridge (D.J.E., B.D.S., D.A.G., W.M.N., D.A.P.) and Groton (C.L.); and Cardiovascular, Metabolic and Endocrine Diseases Research Unit, Cambridge (J.-P.F., X.L., M.J.) Pfizer, Inc.
Margaret Jackson
Pharmacokinetics, Dynamics and Metabolism–New Chemical Entities, Groton, Connecticut (H.E., R.S., T.S.M.) and Cambridge, Massachusetts (A.S.K.); Cardiovascular, Metabolic and Endocrine Diseases Medicinal Chemistry, Cambridge (D.J.E., B.D.S., D.A.G., W.M.N., D.A.P.) and Groton (C.L.); and Cardiovascular, Metabolic and Endocrine Diseases Research Unit, Cambridge (J.-P.F., X.L., M.J.) Pfizer, Inc.
Amit S. Kalgutkar
Pharmacokinetics, Dynamics and Metabolism–New Chemical Entities, Groton, Connecticut (H.E., R.S., T.S.M.) and Cambridge, Massachusetts (A.S.K.); Cardiovascular, Metabolic and Endocrine Diseases Medicinal Chemistry, Cambridge (D.J.E., B.D.S., D.A.G., W.M.N., D.A.P.) and Groton (C.L.); and Cardiovascular, Metabolic and Endocrine Diseases Research Unit, Cambridge (J.-P.F., X.L., M.J.) Pfizer, Inc.
DMD articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|
Log in using your username and password
Purchase access
You may purchase access to this article. This will require you to create an account if you don't already have one.
In this issue
Research ArticleArticle
Intrinsic Electrophilicity of BETP
Heather Eng, Raman Sharma, Thomas S. McDonald, David J. Edmonds, Jean-Philippe Fortin, Xianping Li, Benjamin D. Stevens, David A. Griffith, Chris Limberakis, Whitney M. Nolte, David A. Price, Margaret Jackson and Amit S. Kalgutkar
Drug Metabolism and Disposition August 1, 2013, 41 (8) 1470-1479; DOI: https://doi.org/10.1124/dmd.113.052183
Research ArticleArticle
Intrinsic Electrophilicity of BETP
Heather Eng, Raman Sharma, Thomas S. McDonald, David J. Edmonds, Jean-Philippe Fortin, Xianping Li, Benjamin D. Stevens, David A. Griffith, Chris Limberakis, Whitney M. Nolte, David A. Price, Margaret Jackson and Amit S. Kalgutkar
Drug Metabolism and Disposition August 1, 2013, 41 (8) 1470-1479; DOI: https://doi.org/10.1124/dmd.113.052183
Jump to section
Related Articles
Cited By...
More in this TOC Section
Similar Articles
Advertisement